Development of a hepatic fibrosis biomarker using Magnetic Resonance Elastography (MRE) and Magnetic Resonance Imaging (MRI)
An AI-based biomarker potentially presenting better performance than existing imaging biomarkers.
• Revenues totalling €9.4m over the first three quarters 2020, higher than 2019 yearly revenue (€9m)
• Q3 revenue of €3.5m, a 50% increase compared to Q3, 2019
• Order backlog of €50.7m
• Cash and cash equivalents of €17.3m
Strong revenue growth, accelerated investments and initial promising results for iBiopsy. Revenue surges 47.9% compared with the first half of 2019 at €5.9m. Order backlog up 40% over six months to €53.6m. Cash and cash equivalents of €19.4m as of June 30, 2020
Read moreMedian Technologies today announced the promising results of a first retrospective study on the implementation of the iBiopsy® platform for the analysis of patients with solid tumor cancer who are likely to be responsive to immuno-oncology treatments such as those based on immune checkpoint inhibitors (ICIs)
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]